Predictive factors for response to docetaxel in human breast cancers (Q36521963)

14 August 2017

1 reference

title

Predictive factors for response to docetaxel in human breast cancers (English)

1 reference

14 August 2017

1 reference

Shinzaburo Noguchi

1

1 reference

14 August 2017

29 June 2006

1 reference

14 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Cancer Science

1 reference

14 August 2017

97

1 reference

14 August 2017

9

1 reference

14 August 2017

813-820

1 reference

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Prediction of docetaxel response in human breast cancer by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Mutational analysis of the class I beta-tubulin gene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Mutational analysis of the beta-tubulin gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Microtubule-targeted anticancer agents and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Inactivation of Bcl-2 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Expression of CYP3A4 in human breast tumour and non-tumour tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Adaptor-tagged competitive PCR: a novel method for measuring relative gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00265.X

10.1111/J.1349-7006.2006.00265.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16805818